Can Genzyme Lower the Ante in Discovery?
Genzyme's added what it hopes will be a lower-cost discovery operation to its product-focused business. It's using tracking stock to keep the expenses off Genzyme Corp.'s P&L, and a pragmatic research approach that won't bet everything on a single technological direction. So far the market's not convinced.
You may also be interested in...
The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.